Eli Lilly and Company
- LLY
- NYSE
- Drug manufacturers
- Diabetes/Insulin Drugs
- Oncology Therapeutics
$1240.34
Today −1.33%Quote Oct 19, 2026, 08:00 PM UTC
+7.65%over the last month
Max drawdown −3.5%From 1-month high −1.3%3 months +5.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Eli Lilly and
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications.
Where the money comes from
Q2 2026 revenue $22.77B
- Cardiometabolic Health$18.35B80.6%
- Oncology$2.57B11.3%
- Immunology$1.42B6.2%
- Neuroscience$429.0M1.9%
Sector
Healthcare
Industry
Drug manufacturers
Exchange
NYSE
Employees
50,000
Market value
$1.17T
Quote Oct 19
Floor
$1234.91
0.4% below price
Resistance
$1277.84
3.0% above price
Price vs analyst targets
45 analysts
Lowest target
$940.00Highest target
$1500.00
$940.00Highest target
$1500.00
- Price $1240.34
- Average target $1345.80
- Analysts' target range
Analysts' average target sits about 9% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about LLYPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free